Rapid screening for EGFR mutations: pros and cons.
Gazdar
Adi F
AF
University of Texas Southwestern Medical Center, Dallas, Texas 75390-8593, USA. adi.gazdar@utsouthwestern.edu
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D018773:Genes, erbB-1 / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D016133:Polymerase Chain Reaction; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000627:therapeutic use
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib